Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTKWM86)

• DTT Name: Opioid receptor mu (MOP)
• Synonyms: hMOP; Mu-type opioid receptor; Mu opioid receptor; Mu opiate receptor; MOR1A; MOR1; MOR-1; M-OR-1
• Gene Name: OPRM1
• DTT Type: Successful target; [1]
• BioChemical Class: GPCR rhodopsin
• UniProt ID: OPRM_HUMAN
• TTD ID: T47768
• Sequence:
  MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
  PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
  STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
  RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
  FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
  YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
  EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP
• Function: Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity. Receptor for endogenous opioids such as beta-endorphin and endomorphin.
• KEGG Pathway:
  Neuroactive ligand-receptor interaction (hsa04080)
  Estrogen signaling pathway (hsa04915)
  Morphine addiction (hsa05032)
• Reactome Pathway:
  G alpha (i) signalling events (R-HSA-418594)
  Peptide ligand-binding receptors (R-HSA-375276)

Molecular Interaction Atlas (MIA) of This DTT

23 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alfentanil	DMVO0UB	Anaesthesia	9A78.6	Approved	[2]
Alvimopan	DMHR8KW	Gastrointestinal disease	DE2Z	Approved	[3]
Anileridine	DMBAUED	Pain	MG30-MG3Z	Approved	[4]
Anileridine Hydrochloride	DMC128O	Pain	MG30-MG3Z	Approved	[5]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[6]
Diphenoxylate	DMO5SZX	Diarrhea	ME05.1	Approved	[7]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[8]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[9]
Hydrocodone	DMQ2JO5	Allergic rhinitis	CA08.0	Approved	[10]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[11]
Levomethadyl Acetate	DM06HG5	Opioid dependence	6C43.2Z	Approved	[12]
Levopropoxyphene Napsylate Anhydrous	DMECB4H	Cough	MD12	Approved	[5]
Methadyl Acetate	DMIRMVB	Opioid dependence	6C43.2Z	Approved	[13]
Methylnaltrexone bromide	DMZTGN2	Opioid-induced constipation	DB32.1	Approved	[14]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[15]
Naldemedine Tosylate	DMGD3YH	Opioid-induced constipation	DB32.1	Approved	[16]
Nalfurafine hcl	DMA9DHW	Uremic pruritus	EC90.10	Approved	[17]
Naloxegol	DML0B41	Opioid-induced constipation	DB32.1	Approved	[18]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[19]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[20]
Propoxyphene Hydrochloride	DMMSOLA	Pain	MG30-MG3Z	Approved	[21]
Remifentanil	DMZTXCH	Anaesthesia	9A78.6	Approved	[1]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[14]

16 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GRT-6005	DMHN3PG	Diabetic neuropathy	8C0Z	Phase 3	[22]
Morphine-6-glucuronide	DMPVW6H	Pain	MG30-MG3Z	Phase 3	[23]
NKTR-181	DM45DS8	Chronic low back pain	MG30.02	Phase 3	[24]
ALKS33	DMF3QN1	Alcohol dependence	6C40.2	Phase 2	[25]
Carfentanil	DM7ADGX	N. A.	N. A.	Phase 2	[26]
Met-enkephalin	DMSZFTP	Pain	MG30-MG3Z	Phase 2	[27]
OPNT001	DMYG1ZQ	Eating disorder	6B82	Phase 2	[28]
ORP-101	DMSH20P	Irritable bowel syndrome	DD91.0	Phase 2	[29]
TD-1211	DMTJMK5	Opioid-induced constipation	DB32.1	Phase 2	[30]
AIKO-150	DMW9ZFS	Opioid dependence	6C43.2Z	Phase 1	[11]
Cyt-1010	DMTV09A	Pain	MG30-MG3Z	Phase 1	[31]
GSK1521498	DM2L7TH	Obesity	5B81	Phase 1	[32]
MCP-201	DMW9YOJ	Pain	MG30-MG3Z	Phase 1	[33]
NOCICEPTIN	DMUPA7C	Headache	8A80-8A84	Phase 1	[34]
SALVINORIN A	DMJ3HQY	Cerebral vasospasm	BA85.Z	Phase 1	[35]
TRV734	DMHD8CF	Chronic pain	MG30	Phase 1	[36]

19 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ADL-5945	DMQM54P	Constipation	DD91.1	Discontinued in Phase 2	[37]
BCH-2687	DM6ANFC	Pain	MG30-MG3Z	Discontinued in Phase 2	[38]
DPI-3290	DMKGXT2	Pain	MG30-MG3Z	Discontinued in Phase 2	[39]
Dynorphin a	DMT2WVP	N. A.	N. A.	Discontinued in Phase 2	[40]
Frakefamide	DMTRBU4	Pain	MG30-MG3Z	Discontinued in Phase 2	[41]
MIRFENTANIL HYDROCHLORIDE	DMT6IUR	Pain	MG30-MG3Z	Discontinued in Phase 2	[42]
Transdur-sufentanil	DMX32RC	Pain	MG30-MG3Z	Discontinued in Phase 2	[43]
TREFENTANIL HYDROCHLORIDE	DME85Z9	Pain	MG30-MG3Z	Discontinued in Phase 2	[44]
ADL-7445	DML1AUZ	Constipation	DD91.1	Discontinued in Phase 1	[37]
KN-203	DM37IH5	Urinary incontinence	MF50.2	Discontinued in Phase 1	[45]
VP004	DMXK8FQ	Substance use disorder	6C4Z	Discontinued in Phase 1	[46]
443C81	DMQ4X7Y	Asthma	CA23	Terminated	[49]
BCH-150	DMNH9A6	Gastrointestinal disease	DE2Z	Terminated	[50]
BIPHALIN	DMKNS10	N. A.	N. A.	Terminated	[51]
DBO-11	DM8GHT2	Cancer related pain	MG30	Terminated	[23]
DBO-17	DMFJ3UW	Cancer related pain	MG30	Terminated	[23]
Sameridine	DMEN6YO	Pain	MG30-MG3Z	Terminated	[52]
SB-213698	DM58PKG	N. A.	N. A.	Terminated	[53]
SNF-9007	DM4CNM9	N. A.	N. A.	Terminated	[54]

2 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GNTI	DMTJRLU	Obesity	5B81	Preclinical	[47]
LY-25582	DM2N637	Obesity	5B81	Preclinical	[48]

449 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[55]
(+/-)-TRANS-U-50488 METHANESULFONATE	DMM2QOX	Discovery agent	N.A.	Investigative	[56]
(-)-cyclorphan	DMC8WS4	Discovery agent	N.A.	Investigative	[57]
(-)-eseroline	DMJD34Q	Discovery agent	N.A.	Investigative	[56]
(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)	DMSCQ64	Discovery agent	N.A.	Investigative	[58]
1,10-bis-(Dmt-Tic-amino)decane	DM9UGFQ	Discovery agent	N.A.	Investigative	[59]
1,4-bis-(Dmt-Tic-amino)butane	DMLBHXN	Discovery agent	N.A.	Investigative	[59]
1,6-bis-(Dmt-Tic-amino)hexane	DMRG2CU	Discovery agent	N.A.	Investigative	[59]
1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane	DMMUZK9	Discovery agent	N.A.	Investigative	[59]
1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol	DMOR9EK	Discovery agent	N.A.	Investigative	[60]
1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol	DMV3FSH	Discovery agent	N.A.	Investigative	[60]
1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol	DMLYO8P	Discovery agent	N.A.	Investigative	[60]
1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol	DMTANPG	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol	DMWHMNY	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol	DMXZFPB	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol	DM1QYS8	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol	DMIT7SH	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol	DM0BQYX	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol	DMWYG8K	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol	DME0BJD	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol	DMRNZD6	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol	DMXT894	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol	DMJDUM5	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(furan-2-yl)piperidin-4-ol	DMMB2GV	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol	DMJ8F60	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol	DMNOZR2	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-benzylpiperidin-4-ol	DMVBR36	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-butylpiperidin-4-ol	DMRN7SC	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-cyclohexylpiperidin-4-ol	DMZVSYD	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-cyclopropylpiperidin-4-ol	DMM94Y2	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-ethoxy-4-phenylpiperidine	DM6PIL2	Discovery agent	N.A.	Investigative	[60]
1-benzhydryl-4-hexylpiperidin-4-ol	DMUK95S	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-isopropylpiperidin-4-ol	DMGYCQ3	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-m-tolylpiperidin-4-ol	DMVJH1S	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-methoxy-4-phenylpiperidine	DMBG0N8	Discovery agent	N.A.	Investigative	[60]
1-benzhydryl-4-o-tolylpiperidin-4-ol	DMVUMSF	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-p-tolylpiperidin-4-ol	DM679RC	Discovery agent	N.A.	Investigative	[61]
1-benzhydryl-4-phenyl-4-propoxypiperidine	DMEB968	Discovery agent	N.A.	Investigative	[60]
1-benzhydryl-4-phenylpiperidin-4-ol	DM7KU1X	Discovery agent	N.A.	Investigative	[62]
1-benzhydryl-4-tert-butylpiperidin-4-ol	DMM5DTF	Discovery agent	N.A.	Investigative	[61]
1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol	DMLRS8I	Discovery agent	N.A.	Investigative	[63]
1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol	DMB1NF0	Discovery agent	N.A.	Investigative	[63]
14-O-phenylpropylnaltrexone	DMI7LXH	Discovery agent	N.A.	Investigative	[64]
17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine	DMUQWPZ	Discovery agent	N.A.	Investigative	[65]
17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine	DM174HN	Discovery agent	N.A.	Investigative	[65]
17-methyl-4'-methyldihydromorphinone	DMMEB64	Discovery agent	N.A.	Investigative	[66]
17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate	DMI4WCQ	Discovery agent	N.A.	Investigative	[65]
2-(2-methylquinolin-4-ylamino)-N-phenylacetamide	DMW75IF	Discovery agent	N.A.	Investigative	[67]
2-Benzylaminomethyl-3-hydroxymorphinan	DM6EMGJ	Discovery agent	N.A.	Investigative	[65]
2-Hydroxymethyl-3-hydroxymorphinan	DM4LMPD	Discovery agent	N.A.	Investigative	[65]
3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone	DMWTP7Y	Discovery agent	N.A.	Investigative	[59]
3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone	DM2Y4A6	Discovery agent	N.A.	Investigative	[59]
3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone	DMJR983	Discovery agent	N.A.	Investigative	[59]
3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone	DMEQBS3	Discovery agent	N.A.	Investigative	[59]
3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole	DM2YKHI	Discovery agent	N.A.	Investigative	[68]
3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol	DM1DQGJ	Discovery agent	N.A.	Investigative	[69]
3-desoxy-3-carboxamidonaltrexone	DMBNA0V	Discovery agent	N.A.	Investigative	[25]
3-Methylfentanyl	DMX71N9	Discovery agent	N.A.	Investigative	[70]
3-Methylthiofentanyl	DMC153X	Discovery agent	N.A.	Investigative	[71]
4-(4-((phenethylamino)methyl)phenoxy)benzamide	DM0QRJ3	Discovery agent	N.A.	Investigative	[72]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[73]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide	DM0XDG6	Discovery agent	N.A.	Investigative	[74]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol	DM8ZRAE	Discovery agent	N.A.	Investigative	[75]
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol	DMVCIJB	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylethyl)piperidin-4-ol	DM6EFLV	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylheptyl)piperidin-4-ol	DMISTXQ	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylhexyl)piperidin-4-ol	DM1GRWY	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylpentyl)piperidin-4-ol	DMZQ7DP	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(1-phenylpropyl)piperidin-4-ol	DMALIQ8	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol	DMFV0JC	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol	DM2MPWC	Discovery agent	N.A.	Investigative	[60]
4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol	DM5R6T4	Discovery agent	N.A.	Investigative	[60]
5-(4-((phenethylamino)methyl)phenoxy)picolinamide	DMZYE8W	Discovery agent	N.A.	Investigative	[72]
6-(2-benzylisoindolin-5-yloxy)nicotinamide	DMUD2R9	Discovery agent	N.A.	Investigative	[48]
6-(2-phenethylisoindolin-5-yloxy)nicotinamide	DMQOJBN	Discovery agent	N.A.	Investigative	[48]
6-(4-((benzylamino)methyl)phenoxy)nicotinamide	DMEM1BA	Discovery agent	N.A.	Investigative	[72]
6-(4-((phenethylamino)methyl)phenoxy)nicotinamide	DM9VD4W	Discovery agent	N.A.	Investigative	[48]
6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide	DMDKOWP	Discovery agent	N.A.	Investigative	[48]
6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide	DMOSDM2	Discovery agent	N.A.	Investigative	[72]
6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide	DMDTMB7	Discovery agent	N.A.	Investigative	[72]
6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol	DMYMJHF	Discovery agent	N.A.	Investigative	[76]
6-desoxonaltrexone	DMGZQNS	Discovery agent	N.A.	Investigative	[25]
6beta-naltrexol HCl	DMZ8PBE	Discovery agent	N.A.	Investigative	[77]
8-azabicyclo[3.2.1]octan-3-yloxy-benzamide	DMQMSZR	Discovery agent	N.A.	Investigative	[78]
8-carboxamidocyclazocine	DMD18V5	Discovery agent	N.A.	Investigative	[79]
Ac-D-pro-L-Phe-D-trp-L-Phe-NH2	DMVDH4I	Discovery agent	N.A.	Investigative	[80]
Ac-L-Phe-D-trp-L-Phe-D-pro-NH2	DMKVU8P	Discovery agent	N.A.	Investigative	[80]
Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG	DM512OP	Discovery agent	N.A.	Investigative	[81]
Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG	DMAHQIV	Discovery agent	N.A.	Investigative	[81]
Ac-RYYRIK-K-(NH2)-YAFGYPS	DM2ND3U	Discovery agent	N.A.	Investigative	[81]
Ac-RYYRIK-K-(NH2)-YRFB	DMNA3F4	Discovery agent	N.A.	Investigative	[81]
Ac-YGGFL-NH2	DMC0TU5	Discovery agent	N.A.	Investigative	[82]
ADC-5510	DMV761D	Movement disorder	8A07-8A0Z	Investigative	[20]
AIKO-151	DMUQ6XH	Opioid dependence	6C43.2Z	Investigative	[20]
AIKO-152	DML5Y1Q	Opioid dependence	6C43.2Z	Investigative	[20]
AKUAMMINE	DM8DYWN	Discovery agent	N.A.	Investigative	[56]
AMINOFENTANYL	DM7Y6AL	Discovery agent	N.A.	Investigative	[83]
Antanal 1	DMGDZ6Q	Discovery agent	N.A.	Investigative	[84]
Antanal 2	DMZSUHY	Discovery agent	N.A.	Investigative	[84]
Benzyl derivative of M6G	DMX8W4G	Discovery agent	N.A.	Investigative	[85]
Beta-endorphin	DM7XC6B	Discovery agent	N.A.	Investigative	[86]
Beta-funaltrexamine	DMJORFK	Discovery agent	N.A.	Investigative	[87]
Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate	DM0WKNI	Discovery agent	N.A.	Investigative	[57]
BREMAZOCINE	DM3EIBU	Discovery agent	N.A.	Investigative	[88]
BUTORPHAN	DM82KPQ	Discovery agent	N.A.	Investigative	[89]
C6S	DM4LIHQ	Discovery agent	N.A.	Investigative	[90]
CARBOXYFENTANYL	DMI7Q61	Discovery agent	N.A.	Investigative	[91]
Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	DMQUB19	Discovery agent	N.A.	Investigative	[92]
Clocinnamox	DMZLMJH	Discovery agent	N.A.	Investigative	[64]
CODEINONE	DM08WPL	Discovery agent	N.A.	Investigative	[93]
CTAP	DMLON9K	Discovery agent	N.A.	Investigative	[94]
CTOP	DM7VAJX	Discovery agent	N.A.	Investigative	[95]
CYCLAZOCINE	DMC6DAZ	Discovery agent	N.A.	Investigative	[89]
CYCLORPHAN	DMB1U8V	Discovery agent	N.A.	Investigative	[89]
CYPRODIME	DMJXCVA	Discovery agent	N.A.	Investigative	[96]
C[L-Ala-D-pro-L-Phe-D-trp]	DMHXTWK	Discovery agent	N.A.	Investigative	[80]
C[L-mTyr-D-pro-L-Phe-D-trp]	DMNHSR0	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-mTyr-D-trp]	DM82ZOM	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-Phe-D-trp]	DM0NTU5	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-Phe-L-trp]	DMCY4L0	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]	DM4M3OP	Discovery agent	N.A.	Investigative	[80]
C[L-Phe-D-pro-L-Tyr-D-trp]	DMADSBT	Discovery agent	N.A.	Investigative	[80]
C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]	DMLB6UA	Discovery agent	N.A.	Investigative	[80]
C[L-Tyr-D-pro-L-Phe-D-trp]	DM7OIY8	Discovery agent	N.A.	Investigative	[80]
D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2	DMUJC97	Discovery agent	N.A.	Investigative	[97]
D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)	DM2EFLA	Discovery agent	N.A.	Investigative	[97]
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)	DMPQHRC	Discovery agent	N.A.	Investigative	[97]
D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2	DMMXA5K	Discovery agent	N.A.	Investigative	[97]
DADLE	DMRM0OW	Discovery agent	N.A.	Investigative	[98]
DAMGO	DMS1DVA	Discovery agent	N.A.	Investigative	[99]
DC6S	DMX9FOB	Discovery agent	N.A.	Investigative	[90]
Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	DMU287Q	Discovery agent	N.A.	Investigative	[100]
DELTORPHIN	DMHOT9P	Discovery agent	N.A.	Investigative	[101]
DELTORPHIN-II	DM9ZWRK	Discovery agent	N.A.	Investigative	[102]
Deprotected cogener of M6G	DMH340E	Discovery agent	N.A.	Investigative	[85]
DERMORPHIN	DMCYQHO	Discovery agent	N.A.	Investigative	[81]
Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	DMSN87T	Discovery agent	N.A.	Investigative	[100]
DIHYDROAKUAMMINE	DMW1ALX	Discovery agent	N.A.	Investigative	[56]
Dihydromorphine	DM4TR0D	Discovery agent	N.A.	Investigative	[103]
Dimepheptanol	DMRMHE8	Discovery agent	N.A.	Investigative	[76]
Dimethylthiambutene	DM7EKAF	Discovery agent	N.A.	Investigative	[104]
Diprenorphine	DMIXPU6	Discovery agent	N.A.	Investigative	[105]
DM3A6S	DM7YXKL	Discovery agent	N.A.	Investigative	[90]
DM3B6S	DML68UF	Discovery agent	N.A.	Investigative	[90]
DM6S	DMAJ0Q8	Discovery agent	N.A.	Investigative	[90]
Dmt-Pro-3,5Dmp-Phe-NH2	DM5WEFK	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Dmp-Phe-NH2	DMGUIR1	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Dmt-Phe-NH2	DM4VEU2	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Emp-Phe-NH2	DM06VGY	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Imp-Phe-NH2	DMXUI1J	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Mmp-Phe-NH2	DM78PFN	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Phe-D-1-Nal-NH2	DM0VCWA	Discovery agent	N.A.	Investigative	[107]
Dmt-Pro-Phe-D-2-Nal-NH2	DMRJVE8	Discovery agent	N.A.	Investigative	[107]
Dmt-Pro-Phe-Phe-NH2	DMM8BIE	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Tmp-Phe-NH2	DMEMQAK	Discovery agent	N.A.	Investigative	[106]
Dmt-Pro-Trp-D-2-Nal-NH2	DMKEV5U	Discovery agent	N.A.	Investigative	[107]
Dmt-Sar-Phe-D-2-Nal-NH	DMHRT0F	Discovery agent	N.A.	Investigative	[108]
DPDPE	DMIRSNA	Discovery agent	N.A.	Investigative	[99]
DSLET	DMSTOB0	Discovery agent	N.A.	Investigative	[20]
dynorphin B	DMSPVLM	Discovery agent	N.A.	Investigative	[20]
Dynorphin(1-8)	DMM92LG	Discovery agent	N.A.	Investigative	[109]
ELAEOCARPENINE	DMRHSCQ	Discovery agent	N.A.	Investigative	[110]
ENDOMORPHIN 2	DMOQWBU	Discovery agent	N.A.	Investigative	[111]
ENDOMORPHIN-1	DMBJUEM	Discovery agent	N.A.	Investigative	[112]
Endomorphins	DMI2RQS	Inflammation	1A00-CA43.1	Investigative	[20]
ethylketocyclazocine	DM9YRCU	Discovery agent	N.A.	Investigative	[20]
Ethylmorphine	DM0YROF	Discovery agent	N.A.	Investigative	[113]
ETONITAZENE	DMFR1SE	Discovery agent	N.A.	Investigative	[114]
Etorphine	DM79YZN	Discovery agent	N.A.	Investigative	[115]
FALCARINDIOL	DMLOV18	Discovery agent	N.A.	Investigative	[116]
FLUPERAMIDE	DMEGL84	Discovery agent	N.A.	Investigative	[117]
H-2',6'-dimethyltyrosine-Tic-OH	DMYOADQ	N. A.	N. A.	Investigative	[118]
H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH	DM7IEU2	Discovery agent	N.A.	Investigative	[118]
H-Aba-ala-Gly-Phe-leu-OH	DM61G0I	Discovery agent	N.A.	Investigative	[27]
H-Aba-ala-Gly-Phe-Met-OH	DMKD94Q	Discovery agent	N.A.	Investigative	[27]
H-Aba-Gly-Gly-Phe-Leu-OH	DMH1L3P	Discovery agent	N.A.	Investigative	[27]
H-Aba-ser-Gly-Phe-Leu-Thr-OH	DMFE3J4	Discovery agent	N.A.	Investigative	[27]
H-Apa-ala-Gly-Phe-leu-OH	DM5SUYP	Discovery agent	N.A.	Investigative	[27]
H-Cdp-ala-Gly-Phe-leu-OH	DMV751G	Discovery agent	N.A.	Investigative	[27]
H-Cdp-Gly-Gly-Phe-Leu-OH	DMVEB8C	Discovery agent	N.A.	Investigative	[27]
H-Cdp-ser-Gly-Phe-Leu-Thr-OH	DMCDLTV	Discovery agent	N.A.	Investigative	[27]
H-Cpa-Gly-Gly-Phe-Met-NH2	DMU6PV8	Discovery agent	N.A.	Investigative	[27]
H-Cpa-Gly-Gly-Phe-Met-OH	DM154G2	Discovery agent	N.A.	Investigative	[27]
H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	DMY4QE6	Discovery agent	N.A.	Investigative	[119]
H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	DM8GC36	Discovery agent	N.A.	Investigative	[119]
H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	DMNAE6J	Discovery agent	N.A.	Investigative	[119]
H-Dmt-Aba-Gly-NH-CH2-Bid	DM9WJZK	Discovery agent	N.A.	Investigative	[120]
H-Dmt-Aba-Gly-NH-CH2-Ph	DM61CMS	Discovery agent	N.A.	Investigative	[120]
H-Dmt-Aba-Gly-NH-Ph	DMCQYIJ	Discovery agent	N.A.	Investigative	[120]
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2	DMHK70B	Discovery agent	N.A.	Investigative	[121]
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH	DMM9EPQ	Discovery agent	N.A.	Investigative	[121]
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2	DM1ZDJ6	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH	DMC3APN	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2	DMY97TN	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH	DMGPAM0	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2	DMOI1U5	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH	DMZBFJ5	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2	DMNS1GX	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH	DMM9TUR	Discovery agent	N.A.	Investigative	[122]
H-Dmt-Tic-Asp-N(Me)-Ph	DM4JP8L	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Asp-NH-Bzl	DMBKOJG	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Asp-NH-Ph	DM3W9FQ	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-D-Asp-N(Me)-Ph	DM483BG	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-D-Asp-NH-Ph	DMUG7X1	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)	DMQSRPD	Discovery agent	N.A.	Investigative	[58]
H-Dmt-Tic-Glu-NH-(CH2)5-NH2	DMF52SH	Discovery agent	N.A.	Investigative	[124]
H-Dmt-Tic-Glu-NH2	DM8A573	Discovery agent	N.A.	Investigative	[124]
H-Dmt-Tic-Gly-N(Me)-Ph	DMHYKBC	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Gly-NH-Bzl	DMM39YW	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Gly-NH-CH2-Bid	DMH6JOU	Discovery agent	N.A.	Investigative	[120]
H-Dmt-Tic-Gly-NH-Ph	DMIZ28H	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph	DM2TY43	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys(Ac)-NH-Ph	DMZH9P5	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys(Z)-NH-CH2-Ph	DMP8HFA	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys(Z)-NH-Ph	DMBXGLA	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys-NH-CH2-Ph	DMDJ9PE	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-Lys-NH-Ph	DMT3Y6E	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H	DMMJ9YN	Discovery agent	N.A.	Investigative	[126]
H-Dmt-Tic-NH-(CH2)6-NH-Phe-H	DM0BGNE	Discovery agent	N.A.	Investigative	[126]
H-Dmt-Tic-NH-(CH2)6-NH-Tic-H	DMQ586T	Discovery agent	N.A.	Investigative	[126]
H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid	DMAU2H6	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid	DM5TZ1J	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)	DMIDLPT	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)	DMNEAQ9	Discovery agent	N.A.	Investigative	[123]
H-Dmt-Tic-NH-CH2-Boa	DM4IUCW	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-Bta	DMZ8C0U	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-CH2-NH2	DMYJAW4	Discovery agent	N.A.	Investigative	[128]
H-Dmt-Tic-NH-CH2-Imid	DMJ2F8M	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-ImidPh	DMKGIQJ	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-Indl	DMNY3A1	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH2-Indn	DMZWUFK	Discovery agent	N.A.	Investigative	[127]
H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid	DM8PJ92	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid	DMQ4ILK	Discovery agent	N.A.	Investigative	[125]
H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid	DMQEDP5	Discovery agent	N.A.	Investigative	[125]
H-mCpa-ala-Gly-Phe-leu-OH	DM17QMV	Discovery agent	N.A.	Investigative	[27]
H-mCpa-ser-Gly-Phe-Leu-Thr-OH	DM8OUHV	Discovery agent	N.A.	Investigative	[27]
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH	DMA2CZL	Discovery agent	N.A.	Investigative	[92]
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2	DM48XV0	Discovery agent	N.A.	Investigative	[129]
H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2	DMXPJHB	Discovery agent	N.A.	Investigative	[129]
H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2	DM7QAES	Discovery agent	N.A.	Investigative	[129]
H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2	DMZSTL5	Discovery agent	N.A.	Investigative	[129]
H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2	DMI7CR9	Discovery agent	N.A.	Investigative	[130]
H-Tyr-c[D-Orn-Aic-Glu]-NH2	DMOTI0P	Discovery agent	N.A.	Investigative	[130]
H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2	DMN2AQO	Discovery agent	N.A.	Investigative	[131]
H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2	DM6ZHWS	Discovery agent	N.A.	Investigative	[131]
H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2	DMDF9AS	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac	DM4VBDW	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H	DM0J8P6	Discovery agent	N.A.	Investigative	[134]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo	DMW50ZQ	Discovery agent	N.A.	Investigative	[134]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H	DMF82C1	Discovery agent	N.A.	Investigative	[134]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc	DM6UWKL	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H	DMSXD63	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac	DMRUD37	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc	DMIPXCZ	Discovery agent	N.A.	Investigative	[133]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H	DMFSKDM	Discovery agent	N.A.	Investigative	[134]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2	DM2K16M	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl	DMRE4ZI	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2	DM1ESMZ	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl	DM56KDV	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl	DMH3YKR	Discovery agent	N.A.	Investigative	[132]
H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2	DMSX8CH	Discovery agent	N.A.	Investigative	[131]
H-Tyr-Gly-Gly-Phe-Met-NH2	DM6D0ZS	Discovery agent	N.A.	Investigative	[27]
H-Tyr-Pro-Ala-Phe-NH2	DMP0CRD	Discovery agent	N.A.	Investigative	[82]
H-Tyr-Pro-Dap(6DMN)-Phe-NH2	DMQUNGC	Discovery agent	N.A.	Investigative	[58]
H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2	DM326GJ	Discovery agent	N.A.	Investigative	[58]
H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H	DMXQUKJ	Discovery agent	N.A.	Investigative	[128]
H-Tyr-Tic-Cha-Phe-OH	DM1VFLG	Discovery agent	N.A.	Investigative	[122]
H-Tyr-Tic-Phe-Phe-OH	DMI0U87	Discovery agent	N.A.	Investigative	[122]
HERKINORIN	DMJXBWV	Discovery agent	N.A.	Investigative	[35]
HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2	DM25KZE	Discovery agent	N.A.	Investigative	[135]
ICI-199441	DMEWZ80	Discovery agent	N.A.	Investigative	[136]
KETOCYCLAZOCINE	DM0RC8M	Discovery agent	N.A.	Investigative	[137]
KIN-3031	DMHEOBY	Pain	MG30-MG3Z	Investigative	[20]
KIN-4044	DMO8JQM	Non-small-cell lung cancer	2C25.Y	Investigative	[20]
KNT-5	DMZF3E9	Discovery agent	N.A.	Investigative	[138]
KNT-62	DM9M5HC	Discovery agent	N.A.	Investigative	[17]
KNT-63	DM0U5N9	Discovery agent	N.A.	Investigative	[17]
KRP-100	DMJX9E1	Discovery agent	N.A.	Investigative	[20]
KRP-110	DME9HZC	Constipation	DD91.1	Investigative	[20]
Leucine-enkephalin	DMT2CZK	Discovery agent	N.A.	Investigative	[109]
LOFENTANIL	DMR2WQE	Discovery agent	N.A.	Investigative	[139]
M3A6S	DMJK1RE	Discovery agent	N.A.	Investigative	[90]
M3B6S	DMAHGBF	Discovery agent	N.A.	Investigative	[90]
M3IBu6S	DM0UOF1	Discovery agent	N.A.	Investigative	[90]
M3P6S	DMXT87E	Discovery agent	N.A.	Investigative	[90]
M3Pr6S	DMMC8RN	Discovery agent	N.A.	Investigative	[90]
M3S	DMWADOY	Discovery agent	N.A.	Investigative	[90]
M6G thiosaccharide analogue	DMRB4YV	Discovery agent	N.A.	Investigative	[85]
M6S	DMFCUN4	Discovery agent	N.A.	Investigative	[90]
MC-CAM	DMAHN4L	Discovery agent	N.A.	Investigative	[140]
MCL-117	DMQIGZ7	Discovery agent	N.A.	Investigative	[57]
MCL-139	DMQ1BDZ	Discovery agent	N.A.	Investigative	[57]
MCL-144	DMW7ZF8	Discovery agent	N.A.	Investigative	[141]
MCL-145	DMJXU67	Discovery agent	N.A.	Investigative	[57]
MCL-147	DMH5SMT	Discovery agent	N.A.	Investigative	[142]
MCL-149	DMTWY94	Discovery agent	N.A.	Investigative	[142]
MCL-153	DMCPW5F	Discovery agent	N.A.	Investigative	[143]
MCL-154	DM3PIHV	Discovery agent	N.A.	Investigative	[143]
MCL-182	DM39YW1	Discovery agent	N.A.	Investigative	[142]
MCL-183	DMVR51Z	Discovery agent	N.A.	Investigative	[142]
MCL-428	DMXBHE4	Discovery agent	N.A.	Investigative	[144]
MCL-429	DM1XH04	Discovery agent	N.A.	Investigative	[144]
MCL-431	DMISHCW	Discovery agent	N.A.	Investigative	[144]
MCL-432	DMPOFAR	Discovery agent	N.A.	Investigative	[144]
MCL-433	DMD3OAQ	Discovery agent	N.A.	Investigative	[144]
MCL-434	DMR31VO	Discovery agent	N.A.	Investigative	[144]
MCL-435	DMLSYD9	Discovery agent	N.A.	Investigative	[144]
MCL-443	DM8LTQ4	Discovery agent	N.A.	Investigative	[144]
MCL-444	DM8HALS	Discovery agent	N.A.	Investigative	[144]
MCL-445	DMR2K4F	Discovery agent	N.A.	Investigative	[142]
MCL-446	DMXF73G	Discovery agent	N.A.	Investigative	[142]
MCL-447	DMSTGNH	Discovery agent	N.A.	Investigative	[142]
MCL-448	DMSJGA9	Discovery agent	N.A.	Investigative	[142]
MCL-449	DMQ890N	Discovery agent	N.A.	Investigative	[144]
MCL-450	DM7I6U8	Discovery agent	N.A.	Investigative	[145]
MCL-451	DMP523A	Discovery agent	N.A.	Investigative	[145]
MCL-457	DMORMGU	Discovery agent	N.A.	Investigative	[142]
MCL-458	DMZN93Y	Discovery agent	N.A.	Investigative	[142]
METAZOCINE	DMB6T23	Discovery agent	N.A.	Investigative	[146]
MM3A6S	DMB74MS	Discovery agent	N.A.	Investigative	[90]
MM3B6S	DM9PGQI	Discovery agent	N.A.	Investigative	[90]
MORPHICEPTIN	DM9A1RY	Discovery agent	N.A.	Investigative	[111]
MORPHINONE	DM9LQIA	Discovery agent	N.A.	Investigative	[93]
MR-1029	DMS7FC6	Discovery agent	N.A.	Investigative	[147]
MR-1526	DM5WMXJ	Discovery agent	N.A.	Investigative	[147]
MR-2034	DMF04AG	Discovery agent	N.A.	Investigative	[137]
MR-2266	DMXWSIU	Discovery agent	N.A.	Investigative	[147]
N-(17-Methylmorphinan-3-yl)-N'-phenylurea	DMFRQ2U	Discovery agent	N.A.	Investigative	[65]
N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea	DMHANU5	Discovery agent	N.A.	Investigative	[65]
N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2	DMFNCQ1	Discovery agent	N.A.	Investigative	[148]
N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2	DM8QTSU	Discovery agent	N.A.	Investigative	[148]
N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2	DMSC9FV	Discovery agent	N.A.	Investigative	[148]
N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine	DM7SEM1	Discovery agent	N.A.	Investigative	[65]
N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine	DMLP9VM	Discovery agent	N.A.	Investigative	[65]
N-isobutylnoroxymorphone	DMN1FIU	Discovery agent	N.A.	Investigative	[149]
NalBzOH	DM0CP36	Discovery agent	N.A.	Investigative	[90]
naloxonazine	DM8ZMNH	Discovery agent	N.A.	Investigative	[95]
Naltrexone-6-alpha-ol	DMRAN5O	Discovery agent	N.A.	Investigative	[137]
naltriben	DMNDOLZ	Discovery agent	N.A.	Investigative	[20]
NCT-400	DM09UFT	Major depressive disorder	6A70.3	Investigative	[20]
NE-2	DMILP0F	Pain	MG30-MG3Z	Investigative	[20]
NORBINALTORPHIMINE	DMLYZOG	Discovery agent	N.A.	Investigative	[150]
normorphine	DMYQGFJ	Discovery agent	N.A.	Investigative	[20]
NRP290	DMC9XJA	Pain	MG30-MG3Z	Investigative	[20]
NRT-300	DM3IWP5	Pain	MG30-MG3Z	Investigative	[20]
O-DESMETHYL TRAMADOL	DM8ZG2I	Discovery agent	N.A.	Investigative	[137]
ORIPAVINE	DMPQGUL	Discovery agent	N.A.	Investigative	[93]
OXYMORPHINDOLE	DMTP4S2	Discovery agent	N.A.	Investigative	[114]
Oxymorphone semicarbazone hydrochloride	DMTSM61	Discovery agent	N.A.	Investigative	[109]
PHENAZOCINE	DMCTVMI	Discovery agent	N.A.	Investigative	[137]
PL017	DMICVXN	Discovery agent	N.A.	Investigative	[94]
PTI-601	DMQUSXK	Pain	MG30-MG3Z	Investigative	[20]
quadazocine	DM2Q6JY	Discovery agent	N.A.	Investigative	[20]
RTI-5989-31	DMZO1QC	Discovery agent	N.A.	Investigative	[151]
SB-0304	DMOZX0D	Discovery agent	N.A.	Investigative	[152]
Semorphone	DM1C5GZ	Discovery agent	N.A.	Investigative	[153]
SL-3111	DM0UE28	Discovery agent	N.A.	Investigative	[154]
SN-11	DMA0JZM	Discovery agent	N.A.	Investigative	[53]
SN-23	DM6O0PD	Discovery agent	N.A.	Investigative	[53]
SN-28	DMB8TJC	Discovery agent	N.A.	Investigative	[155]
SOMATOSTATIN	DMIOFQE	Acromegaly	5A60.0	Investigative	[97]
SPIROINDANYLOXYMORPHONE	DMNJVZU	Discovery agent	N.A.	Investigative	[156]
THEBAINE	DMRCD3O	Discovery agent	N.A.	Investigative	[93]
TQ-1017	DMEF32D	Pain	MG30-MG3Z	Investigative	[157]
Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	DMBU4KJ	Discovery agent	N.A.	Investigative	[92]
Tyr-(NMe)Ala-L-Phe-D-Pro-NH2	DMIWPKB	Discovery agent	N.A.	Investigative	[158]
Tyr-(R)-Aba-Gly-Phe-NH2	DMDQJUO	Discovery agent	N.A.	Investigative	[159]
Tyr-(R)-spiro-Aba-Gly-Phe-NH2	DMHNM3K	Discovery agent	N.A.	Investigative	[159]
Tyr-(S)-Aba-Gly-Phe-NH2	DMYZ792	Discovery agent	N.A.	Investigative	[159]
Tyr-(S)-spiro-Aba-Gly-Phe-NH2	DMT316S	Discovery agent	N.A.	Investigative	[159]
Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2	DM0D1Z5	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2	DMPH1G0	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Ala-Gly-NMePhe	DM2XRZL	Discovery agent	N.A.	Investigative	[87]
Tyr-D-Ala-Gly-Phe-Met-NH2	DMC7LND	Discovery agent	N.A.	Investigative	[51]
Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl	DMWOP9N	Discovery agent	N.A.	Investigative	[160]
Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc	DMB2TCF	Discovery agent	N.A.	Investigative	[133]
Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2	DMUXMVQ	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2	DMREJ69	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2	DMTPLNZ	Discovery agent	N.A.	Investigative	[161]
Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2	DMC4NO5	Discovery agent	N.A.	Investigative	[162]
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2	DM4FASR	Discovery agent	N.A.	Investigative	[161]
Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2	DMB9A46	Discovery agent	N.A.	Investigative	[161]
Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2	DMLC0NW	Discovery agent	N.A.	Investigative	[161]
Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2	DM4YTFP	Discovery agent	N.A.	Investigative	[162]
Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2	DMY9NIJ	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2	DMQREP2	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2	DMZ24LN	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2	DMPSJ72	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2	DMIWMN6	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2	DM2CEWT	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2	DMKM81A	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2	DMZOTGM	Discovery agent	N.A.	Investigative	[54]
Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2	DMM9H07	Discovery agent	N.A.	Investigative	[54]
Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2	DMN7290	Discovery agent	N.A.	Investigative	[54]
Tyr-Pro-3,5Dmp-Phe-NH2	DMDCJWU	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-D-(NMe)Phe-D-Pro-NH2	DMH08O3	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-D-Phe-D-Pro-NH2	DM4ZJR5	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-D-Phe-Pro-NH2	DMCTSNE	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-D-Phg-Phe-NH2	DMEDVRN	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Dmp-Phe-NH2	DMNXCHT	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Dmt-Phe-NH2	DMOU43H	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Emp-Phe-NH2	DMUKE43	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Hfe-Phe-NH2	DME5HIS	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Hfe-Pro-NH2	DMJBR75	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Imp-Phe-NH2	DMUV3ZW	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-L-(NMe)Phe-D-Pro-NH2	DMI65GV	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-L-(NMe)Phe-Pro-NH2	DM1NITL	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-L-Phe-D-Pro-NH2	DMUVHGS	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-L-Phe-Pro-NH2	DM8VW3Z	Discovery agent	N.A.	Investigative	[158]
Tyr-Pro-Mmp-Phe-NH	DMRE7G3	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Phe-Ala-Bn	DMIE4U5	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Phe-D-2-Nal-NH2	DMLQ3PR	Discovery agent	N.A.	Investigative	[108]
Tyr-Pro-Phe-D-Ala-Bn	DMLEUF6	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Phe-D-Phg-NH2	DM6YRVT	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Phe-D-Val-Bn	DM1QZ9X	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Phe-Hfe-NH2	DM71P2O	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Phe-Phe-N(CH3)2	DM5DRIZ	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-NHCH3	DM2U4VI	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-NHNH2	DMY6V9R	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-OC(CH3)3	DMS4P1E	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-OCH2CH3	DMZNHEC	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-OCH2OH	DMFV7NI	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phe-OCH3	DMRQXHO	Discovery agent	N.A.	Investigative	[165]
Tyr-Pro-Phe-Phg-NH2	DM70HYT	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Phg-Phe-NH2	DMVDM73	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Phg-Pro-NH2	DMSGMPU	Discovery agent	N.A.	Investigative	[163]
Tyr-Pro-Tmp-Phe-NH	DMR3IVB	Discovery agent	N.A.	Investigative	[106]
Tyr-Pro-Trp-D-Ala-Bn	DMFIPXA	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Trp-D-Val-Bn	DMY5HX6	Discovery agent	N.A.	Investigative	[164]
Tyr-Pro-Trp-Gly-Bn	DMKLDWF	Discovery agent	N.A.	Investigative	[164]
Tyr-Sar-Phe-D-2-Nal-NH2	DMIZB25	Discovery agent	N.A.	Investigative	[108]
UFP-502	DMD8BRG	Discovery agent	N.A.	Investigative	[102]
UFP-512	DMYPVSJ	Discovery agent	N.A.	Investigative	[102]
YAWF-NH2	DMUW4KG	Discovery agent	N.A.	Investigative	[82]
YGGWL-NH2	DM5LYKW	Discovery agent	N.A.	Investigative	[82]
YGWFL-NH2	DMQ2EYJ	Discovery agent	N.A.	Investigative	[82]
YPAA-NH2	DMC3DK5	Discovery agent	N.A.	Investigative	[82]
YPWA-NH2	DMOTHAC	Discovery agent	N.A.	Investigative	[82]
YRFB	DMXOJIB	Discovery agent	N.A.	Investigative	[81]
ZYKLOPHIN	DM0S5PE	Discovery agent	N.A.	Investigative	[135]
[3H]diprenorphine	DMBMS1U	Discovery agent	N.A.	Investigative	[95]
[3H]U69593	DM6RSZ9	Discovery agent	N.A.	Investigative	[90]
[D-Ala2]Met-enkephalinamide	DM18ZNJ	Discovery agent	N.A.	Investigative	[146]
[Dcp1]Dyn A(1-11)-NH2	DM23GCK	Discovery agent	N.A.	Investigative	[100]
[Leu5]enkephalin	DMA0N32	Discovery agent	N.A.	Investigative	[166]
[Tyr-Pro-Phe-NH-CH2-]2	DMZTRQ0	Discovery agent	N.A.	Investigative	[167]
[Tyr-Pro-Phe-NH-]2	DM61RG2	Discovery agent	N.A.	Investigative	[167]
[Tyr-Pro-Phe-Phe-NH-CH2-]2	DMFGO4W	Discovery agent	N.A.	Investigative	[167]
[Tyr-Pro-Phe-Phe-NH-]2	DME6TNL	Discovery agent	N.A.	Investigative	[167]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Major depressive disorder	6A20	Pre-frontal cortex	5.94E-01	-0.02	-0.17
Asthma	CA23	Nasal and bronchial airway	7.39E-01	3.94E-03	0.02
Lung cancer	2C82	Lung tissue	1.72E-01	0.02	0.11
Irritable bowel syndrome	DD91.0	Rectal colon tissue	7.80E-01	0.09	0.31

References

• [1] The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevent... Pain. 2009 Jan;141(1-2):88-96.
• [2] Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
• [3] Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77.
• [4] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
• [7] Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
• [8] Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
• [9] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [10] Clinical pipeline report, company report or official report of kempharm.
• [11] Clinical pipeline report, company report or official report of signaturerx.
• [12] Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
• [13] Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9.
• [14] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [15] Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
• [16] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [17] Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
• [18] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [19] OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7.
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [21] Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78.
• [22] Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth. 2015 Mar;114(3):364-6.
• [23] Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
• [24] A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain. P T. 2012 July; 37(7): 412-418.
• [25] Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
• [26] Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
• [27] Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
• [28] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [29] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [30] The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91.
• [31] Endomorphin-2: A Biased Agonist at the -Opioid Receptor. Mol Pharmacol. 2012 August; 82(2): 178-188.
• [32] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [33] US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same.
• [34] Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists. J Med Chem. 2008 Feb 28;51(4):1058-62.
• [35] Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31.
• [36] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [37] Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56.
• [38] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009073)
• [39] DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function. J Pharmacol Exp Ther. 2003 Dec;307(3):1227-33.
• [40] Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71.
• [41] A novel molecule (frakefamide) with peripheral opioid properties: the effects on resting ventilation compared with morphine and placebo. Anesth Analg. 2005 Mar;100(3):713-7, table of contents.
• [42] Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J Pharmacol Exp Ther. 1991 Aug;258(2):502-10.
• [43] [3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol. 1983 Feb 18;87(2-3):209-25.
• [44] Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. Clin Pharmacol Ther. 1994 Sep;56(3):261-71.
• [45] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026307)
• [46] WO patent application no. 2007,0677,14, Treatment of sequelae of psychiatric disorders.
• [47] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [48] Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
• [49] Inhibition of cholinergic neurotransmission in human airways by opioids. J Appl Physiol (1985). 1992 Mar;72(3):1096-100.
• [50] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003724)
• [51] Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing tw... J Med Chem. 2010 Aug 12;53(15):5491-501.
• [52] The effects on resting ventilation of intravenous infusions of morphine or sameridine, a novel molecule with both local anesthetic and opioid properties. Anesth Analg. 1999 Jan;88(1):160-5.
• [53] Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
• [54] Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
• [55] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [56] Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4.
• [57] Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
• [58] 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
• [59] Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
• [60] Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
• [61] Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
• [62] The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23.
• [63] Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7.
• [64] 14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7.
• [65] Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
• [66] Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorp... J Med Chem. 2006 Aug 24;49(17):5333-8.
• [67] Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic ... Bioorg Med Chem. 2009 Aug 15;17(16):5782-90.
• [68] 3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8.
• [69] Phenylmorphans and analogues: opioid receptor subtype selectivity and effect of conformation on activity. J Med Chem. 1992 May 1;35(9):1521-5.
• [70] Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91.
• [71] You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83.
• [72] Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
• [73] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [74] Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
• [75] Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
• [76] Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6.
• [77] Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4.
• [78] SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10.
• [79] Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-c... Bioorg Med Chem. 2008 May 15;16(10):5653-64.
• [80] Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
• [81] Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41.
• [82] Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6.
• [83] Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4946-50.
• [84] Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70.
• [85] Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
• [86] Beta-endorphin is a potent inhibitor of thymidine incorporation into DNA via mu- and kappa-opioid receptors in fetal rat brain cell aggregates in culture. J Neurochem. 1993 Feb;60(2):765-7.
• [87] Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors. J Med Chem. 2009 Dec 10;52(23):7372-5.
• [88] Electrophilic alpha-methylene-gamma-lactone and isothiocyanate opioid ligands related to etorphine. J Med Chem. 1990 Aug;33(8):2286-96.
• [89] Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22.
• [90] Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
• [91] Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem. 2007 Nov 1;50(22):5528-32.
• [92] Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
• [93] Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32.
• [94] Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther. 1983 Nov;227(2):403-8.
• [95] Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4.
• [96] Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonis... J Med Chem. 2004 Jun 3;47(12):3242-7.
• [97] Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
• [98] Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokini... J Med Chem. 2007 Jun 14;50(12):2779-86.
• [99] Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82.
• [100] Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
• [101] Synthesis and structure-activity relationships of deltorphin analogues. J Med Chem. 1991 May;34(5):1656-61.
• [102] Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30.
• [103] Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5.
• [104] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [105] [6-O-methyl-11C]Diprenorphine Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
• [106] Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
• [107] Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20.
• [108] Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3.
• [109] Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5.
• [110] Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3.
• [111] Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur J Med Chem. 2010 Oct;45(10):4594-600.
• [112] Synthesis and evaluation of new endomorphin analogues modified at the Pro(2) residue. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4115-8.
• [113] Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20.
• [114] Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15.
• [115] Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus. Neuroscience. 2001;108(3):467-77.
• [116] Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23.
• [117] Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9.
• [118] Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5.
• [119] Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80.
• [120] New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
• [121] From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11.
• [122] Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
• [123] Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
• [124] Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6.
• [125] Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
• [126] New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20.
• [127] Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
• [128] A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81.
• [129] Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
• [130] Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32.
• [131] Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors. J Med Chem. 1993 Nov 26;36(24):3748-56.
• [132] A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
• [133] Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
• [134] Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
• [135] The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21.
• [136] Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide. J Med Chem. 1994 Sep 2;37(18):2856-64.
• [137] Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
• [138] Investigation of Beckett-Casy model 1: synthesis of novel 16,17-seco-naltrexone derivatives and their pharmacology. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1055-8.
• [139] Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem. 1982 Aug;25(8):913-9.
• [140] 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid rece... J Med Chem. 2009 Nov 12;52(21):6926-30.
• [141] Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10;52(23):7389-96.
• [142] In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
• [143] Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
• [144] High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
• [145] New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3.
• [146] Synthesis and biological evaluation of a metazocine-containing enkephalinamide. Evidence for nonidentical roles of the tyramine moiety in opiates a... J Med Chem. 1982 Dec;25(12):1423-7.
• [147] Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44.
• [148] Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702.
• [149] Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4978-81.
• [150] Synthesis of pyrrolomorphinan derivatives as kappa opioid agonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5035-8.
• [151] Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an ... J Med Chem. 2007 Aug 9;50(16):3765-76.
• [152] Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem. 2008 Apr 24;51(8):2571-4.
• [153] Respiratory effects and tolerability of Mr 2264 Cl.A new opiate partial agonist in comparison with morphine and placebo.Eur J Clin Pharmacol.1994;46(4):301-4.
• [154] Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selecti... J Med Chem. 1999 Dec 30;42(26):5359-68.
• [155] Design and synthesis of KNT-127, a -opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5.
• [156] Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normo... Bioorg Med Chem. 2009 Aug 15;17(16):5983-8.
• [157] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [158] A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
• [159] Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
• [160] The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47.
• [161] Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
• [162] Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5.
• [163] Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
• [164] Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91.
• [165] Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
• [166] Carba-analogues of fentanyl are opioid receptor agonists. J Med Chem. 2010 Apr 8;53(7):2875-81.
• [167] Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.